Five-year real-world drug survival of dupilumab in severe atopic dermatitis and associate predictors
This investigation establishes dupilumab's enduring efficacy and safety in severe AD, emphasizing its potential as a sustained therapeutic option over 5+ years. Baseline characteristics did not seem to influence DS, with the exception of the nummular eczema-like phenotype, which emerged as a significant predictor of psoriasis occurrence.
Authors
- Angelo Valerio Marzano (ORCID: https://orcid.org/0000-0002-2258-8357)
- Paolo Calzari (ORCID: https://orcid.org/0000-0001-7690-7221)
- Gabriele Perego (ORCID: https://orcid.org/0009-0008-3547-5168)
- Alessandra Chiei Gallo (ORCID: https://orcid.org/0000-0001-8028-5453)
- Martina Zussino (ORCID: https://orcid.org/0000-0003-0999-9183)
- Simona Tavecchio (ORCID: https://orcid.org/0000-0003-3546-4932)
- Francesca Barei (ORCID: https://orcid.org/0000-0002-7188-7310)
- Luca Valtellini (ORCID: https://orcid.org/0009-0000-6479-0986)
- Silvia Ferrucci
Institutions
- University of Milan (IT)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Publication Details
- Journal
- Journal of Dermatological Treatment
- Published
- 2024-10-13
- DOI
- https://doi.org/10.1080/09546634.2024.2404718
- Citations
- 12
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.42